Quince Therapeutics Inc. (QNCX)
NASDAQ: QNCX
· Real-Time Price · USD
1.35
-0.03 (-2.17%)
At close: Jun 17, 2025, 3:59 PM
1.36
0.74%
After-hours: Jun 17, 2025, 04:04 PM EDT
-2.17% (1D)
| Bid | 1.3 |
| Market Cap | 61.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.71M |
| EPS (ttm) | -1.39 |
| PE Ratio (ttm) | -0.97 |
| Forward PE | -2.08 |
| Analyst | Buy |
| Ask | 1.38 |
| Volume | 64,619 |
| Avg. Volume (20D) | 319,588 |
| Open | 1.33 |
| Previous Close | 1.38 |
| Day's Range | 1.29 - 1.38 |
| 52-Week Range | 0.51 - 2.45 |
| Beta | 0.80 |
About QNCX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol QNCX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for QNCX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 days ago
+19.17%
Quince Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
7 months ago
+19.5%
Quince Therapeutics shares are trading higher after the company reported a year-over-year increase in Q3 EPS results.
1 month ago · seekingalpha.com
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026Quince Therapeutics is advancing eDSP for Ataxia-Telangiectasia, leveraging strong prior data in the 6-9 age group and an innovative AIDE platform. Recent insider buying, new analyst coverage with hig...
1 month ago · businesswire.com
Quince Therapeutics to Present at Citizens Life Sciences ConferenceSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog...
